Evotec
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
| Company type | Public (Societas Europaea) |
|---|---|
Traded as | FWB: EVT FWB: EVTA (ADR) WBAG: EVT Nasdaq: EVO (ADR) MDAX component (FWB: EVT) |
| ISIN | DE0005664809 US30050E1055 |
| Industry | Biotechnology, contract research organization |
| Founded | 1993 |
| Headquarters | Hamburg, Germany |
Key people | Werner Lanthaler (CEO)
Iris Löw-Friedrich (Chairwoman of the Supervisory Board) Manfred Eigen (Cofounder) |
| Revenue | 618 million € (2021) |
Number of employees | >4,200 (2021) |
| Website | www.evotec.com |
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology (e.g. Alzheimer's disease, Huntington's disease), metabolic diseases (e.g. Diabetes), Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. On 8 November 2021, Evotec completed its secondary listing on the U.S. Nasdaq stock exchange on November 8 and raised $500 million.